Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
MERCK reported better-than-expected third-quarter earnings yesterday thanks to cost cutting, but lower sales of its Januvia diabetes treatment added fresh evidence that its biggest product has been losing ground to newer drugs.
Moreover, sales of Merck?s animal health products, which typically prop up results, fell two per cent in the third quarter, hurt by the recent decision to suspend sales of its Zilmax weight-gain feed supplement amid concerns it was causing lameness in cattle.
http://www.cityam.com/article/1383010746/merck-suffers-slump-sales-diabetes-drug-and-animal-feed
Moreover, sales of Merck?s animal health products, which typically prop up results, fell two per cent in the third quarter, hurt by the recent decision to suspend sales of its Zilmax weight-gain feed supplement amid concerns it was causing lameness in cattle.
http://www.cityam.com/article/1383010746/merck-suffers-slump-sales-diabetes-drug-and-animal-feed